IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 20, 2013, Pages 8158-8163

  Liu, Rebecca Berlant ^a   Engels, Boris ^a   Schreiber, Karin ^a   Ciszewski, Cezary ^a   Schietinger, Andrea ^a,b   Schreiber, Hans ^a   Jabri, Bana ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

NK receptors; NKG2D

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 15; LYMPHOKINE; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CANCER CONTROL; CANCER RECURRENCE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR REGRESSION;

NK RECEPTORS; NKG2D;

ANIMALS; ANTIGENS, NEOPLASM; AUTOIMMUNITY; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GREEN FLUORESCENT PROTEINS; HUMANS; INTERLEUKIN-15; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS; PERFORIN; RECEPTORS, ANTIGEN, T-CELL; SPLEEN; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84877845953     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1301022110     Document Type: Article

References (39)

1. Naito Y, et al. (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58(16):3491-3494. (Pubitemid 28376536)
2. Zhang L, et al. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3):203-213. (Pubitemid 36077915)
3. Pagès F, et al. (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353(25):2654-2666. (Pubitemid 41817714)
4. Sato E, et al. (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102(51):18538-18543. (Pubitemid 43011261)
5. Spiotto MT, et al. (2002) Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17(6):737-747. (Pubitemid 35477793)
6. Urban JL, Burton RC, Holland JM, Kripke ML, Schreiber H (1982) Mechanisms of syngeneic tumor rejection: Susceptibility of host-selected progressor variants to various immunological effector cells. J Exp Med 155(2):557-573. (Pubitemid 12171298)
7. Uyttenhove C, Maryanski J, Boon T (1983) Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 157(3):1040-1052. (Pubitemid 13117080)
8. Yee C, et al. (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99(25): 16168-16173. (Pubitemid 35462767)
9. Giri JG, et al. (1995) IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2. J Leukoc Biol 57(5):763-766.
10. Carson WE, et al. (1994) Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 180(4):1395-1403. (Pubitemid 24289613)
11. Waldmann TA (2004) Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases. Arthritis Res Ther 6(4):174-177. (Pubitemid 39162380)
12. Jabri B, Sollid LM (2009) Tissue-mediated control of immunopathology in coeliac disease. Nat Rev Immunol 9(12):858-870.
13. Roberts AI, et al. (2001) NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol 167(10):5527-5530. (Pubitemid 33062738)
14. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T (2003) Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci USA 100(16):9452-9457. (Pubitemid 37033949)
15. Meresse B, et al. (2004) Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21(3):357-366. (Pubitemid 39208337)
16. Gamero AM, Ussery D, Reintgen DS, Puleo CA, Djeu JY (1995) Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism. Cancer Res 55(21):4988-4994.
17. Tang F, et al. (2009) Cytosolic PLA2 is required for CTL-mediated immunopathology of celiac disease via NKG2D and IL-15. J Exp Med 206(3):707-719.
18. Green PH, Jabri B (2003) Coeliac disease. Lancet 362(9381):383-391. (Pubitemid 36945070)
19. Hüe S, et al. (2004) A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 21(3):367-377. (Pubitemid 39208338)
20. Klebanoff CA, et al. (2004) IL-15 enhances the in vivo antitumor activity of tumorreactive CD8+ T cells. Proc Natl Acad Sci USA 101(7):1969-1974. (Pubitemid 38228999)
21. Teague RM, et al. (2006) Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med 12(3):335-341. (Pubitemid 43355083)
22. Mueller K, Schweier O, Pircher H (2008) Efficacy of IL-2-versus IL-15-stimulated CD8 T cells in adoptive immunotherapy. Eur J Immunol 38(10):2874-2885.
23. Roychowdhury S, et al. (2004) Failed adoptive immunotherapy with tumor-specific T cells: Reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Res 64(21):8062-8067. (Pubitemid 39446944)
24. Dubois S, Patel HJ, Zhang M, Waldmann TA, Müller JR (2008) Preassociation of IL-15 with IL-15R α-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J Immunol 180(4):2099-2106.
25. Epardaud M, et al. (2008) Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res 68(8):2972-2983. (Pubitemid 351556298)
26. Kobayashi H, et al. (2005) Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 105(2):721-727. (Pubitemid 40070758)
27. Liu RB, et al. (2012) Densely granulated murine NK cells eradicate large solid tumors. Cancer Res 72(8):1964-1974.
28. Sato N, Patel HJ, Waldmann TA, Tagaya Y (2007) The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. Proc Natl Acad Sci USA 104(2):588-593. (Pubitemid 46123069)
29. Mortier E, Woo T, Advincula R, Gozalo S, Ma A (2008) IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med 205(5):1213-1225. (Pubitemid 351679694)
30. Budagian V, Bulanova E, Paus R, Bulfone-Paus S (2006) IL-15/IL-15 receptor biology: A guided tour through an expanding universe. Cytokine Growth Factor Rev 17(4): 259-280. (Pubitemid 44038618)
31. Spiotto MT, Rowley DA, Schreiber H (2004) Bystander elimination of antigen loss variants in established tumors. Nat Med 10(3):294-298. (Pubitemid 38667621)
32. Fehniger TA, et al. (2001) Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med 193(2):219-231. (Pubitemid 32524453)
33. Cerwenka A, et al. (2000) Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12(6):721-727.
34. Zhang B, Karrison T, Rowley DA, Schreiber H (2008) IFN-gamma-and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest 118(4):1398-1404. (Pubitemid 351500433)
35. Garcia-Hernandez MdeL, et al. (2010) Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol 184(8): 4215-4227.
36. Kroemer A, et al. (2008) The innate NK cells, allograft rejection, and a key role for IL-15. J Immunol 180(12):7818-7826.
37. Chmielewski M, Abken H (2012) CAR T cells transform to trucks: Chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol Immunother 61(8):1269-1277.
38. Vugmeyster Y, et al. (1998) Major histocompatibility complex (MHC) class I KbDb-/-deficient mice possess functional CD8+ T cells and natural killer cells. Proc Natl Acad Sci USA 95(21):12492-12497. (Pubitemid 28483792)
39. Sommermeyer D, et al. (2006) Designer T cells by T cell receptor replacement. Eur J Immunol 36(11):3052-3059. (Pubitemid 44782577)